Literature DB >> 32955582

Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era.

Feras Akbik1, Haolin Xu2, Ying Xian2, Shreyansh Shah2, Eric E Smith3, Deepak L Bhatt4,5, Roland A Matsouaka2,6, Gregg C Fonarow7, Lee H Schwamm8.   

Abstract

Importance: A significant proportion of acute ischemic strokes occur while patients are hospitalized. Limited contemporary data exist on the utilization rates of intravenous thrombolysis or endovascular therapy for in-hospital stroke. Objective: To use a national registry to examine temporal trends in the use of intravenous and endovascular reperfusion therapies for treatment of in-hospital stroke. Design, Setting, and Participants: This retrospective cohort study analyzed data from 267 956 patients who underwent reperfusion therapy for stroke with in-hospital or out-of-hospital onset reported in the Get With the Guidelines-Stroke national registry from January 2008 to September 2018. Exposures: In-hospital onset vs out-of-hospital onset of stroke symptoms. Main Outcomes and Measures: Temporal trends in the use of reperfusion therapy, process measures of quality, and the association between functional outcomes and key patient characteristics, comorbidities, and treatments.
Results: Of 67 493 patients with in-hospital stroke onset, this study observed increased rates of vascular risk factors (standardized mean difference >10%) but no significant differences in age or sex in patients undergoing intravenous thrombolysis only (mean [interquartile range {IQR}] age, 72 [80-62] y; 53.2% female) or those undergoing endovascular therapy (mean [IQR] age, 69 [59-79] y; 49.8% female). Of these patients, 10 481 (15.5%) received intravenous thrombolysis and 2494 (3.7%) underwent endovascular therapy. Compared with 2008, in 2018 the proportion of in-hospital stroke among all stroke hospital discharges was higher (3.5% vs 2.7%; P < .001), as was use of intravenous thrombolysis (19.1% vs 9.1%; P < .001) and endovascular therapy (6.4% vs 2.5%; P < .001) in patients with in-hospital stroke, with a significant increase in endovascular therapy in mid-2015 (P < .001). Compared with patients who received intravenous thrombolysis for out-of-hospital stroke onset, those with in-hospital onset were associated with longer median (IQR) times from stroke recognition to cranial imaging (33 [18-60] vs 16 [9-26] minutes; P < .001) and to thrombolysis bolus (81 [52-125] vs 60 [45-84] minutes; P < .001). In adjusted analyses, patients with in-hospital stroke onset who were treated with intravenous thrombolysis were less likely to ambulate independently at discharge (adjusted odds ratio, 0.78; 95% CI, 0.74-0.82; P < .001) and were more likely to die or to be discharged to hospice (adjusted odds ratio, 1.39; 95% CI, 1.29-1.50; P < .001) than patients with out-of-hospital onset who also received intravenous thrombolysis treatment. Comparisons among patients treated with endovascular therapy yielded similar findings. Conclusions and Relevance: In this cohort study, in-hospital stroke onset was increasingly reported and treated with reperfusion therapy. Compared with out-of-hospital stroke onset, in-hospital onset was associated with longer delays to reperfusion and worse functional outcomes, highlighting opportunities to further care for patients with in-hospital stroke onset.

Entities:  

Mesh:

Year:  2020        PMID: 32955582      PMCID: PMC7506601          DOI: 10.1001/jamaneurol.2020.3362

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  7 in total

1.  Comparing characteristics and outcomes of in-hospital stroke and community-onset stroke.

Authors:  Zi-Yue Liu; Guang-Song Han; Juan-Juan Wu; Yu-Hui Sha; Yue-Hui Hong; Han-Hui Fu; Li-Xin Zhou; Jun Ni; Yi-Cheng Zhu
Journal:  J Neurol       Date:  2022-07-02       Impact factor: 6.682

2.  In-Hospital Stroke Care: A Six-Year Community-Based Primary Stroke Center Experience.

Authors:  Felix Ejike Chukwudelunzu; Bart M Demaerschalk; Leonardo Fugoso; Emeka Amadi; Donn Dexter; Angela Gullicksrud; Clinton Hagen
Journal:  Neurohospitalist       Date:  2021-05-03

Review 3.  Impact of mobile stroke units.

Authors:  Klaus Fassbender; Fatma Merzou; Martin Lesmeister; Silke Walter; Iris Quasar Grunwald; Andreas Ragoschke-Schumm; Thomas Bertsch; James Grotta
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-05-25       Impact factor: 10.154

4.  Comparison of Clinical Features, Immune-Inflammatory Markers, and Outcomes Between Patients with Acute In-Hospital and Out-of-Hospital Ischemic Stroke.

Authors:  Pei-Ya Chen; Guei-Chiuan Chen; Cheng-Lun Hsiao; Po-Jen Hsu; Fu-Yi Yang; Chih-Yang Liu; Adam Tsou; Wan-Ling Chang; Hsiu-Hsun Liu; Shinn-Kuang Lin
Journal:  J Inflamm Res       Date:  2022-02-09

Review 5.  Progresses and Prospects of Neuroprotective Agents-Loaded Nanoparticles and Biomimetic Material in Ischemic Stroke.

Authors:  Junfa Chen; Jing Jin; Kaiqiang Li; Lin Shi; Xuehua Wen; Fuquan Fang
Journal:  Front Cell Neurosci       Date:  2022-04-11       Impact factor: 5.505

6.  Negative correlation between early recovery and lipoprotein-associated phospholipase A2 levels after intravenous thrombolysis.

Authors:  Yanzheng Li; Wei Wang; Hang Yang; Weiheng Guo; Jingyu Feng; Dejiu Yang; Li Guo; Guojun Tan
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.573

7.  Effectiveness and safety of EVT in patients with acute LVO and low NIHSS.

Authors:  Beom Joon Kim; Bijoy K Menon; Joonsang Yoo; Jung Hoon Han; Bum Joon Kim; Chi Kyung Kim; Jae Guk Kim; Joon-Tae Kim; Hyungjong Park; Sung Hyun Baik; Moon-Ku Han; Jihoon Kang; Jun Yup Kim; Keon-Joo Lee; Jong-Moo Park; Kyusik Kang; Soo Joo Lee; Jae-Kwan Cha; Dae-Hyun Kim; Jin-Heon Jeong; Tai Hwan Park; Sang-Soon Park; Kyung Bok Lee; Jun Lee; Keun-Sik Hong; Yong-Jin Cho; Hong-Kyun Park; Byung-Chul Lee; Kyung-Ho Yu; Mi-Sun Oh; Dong-Eog Kim; Wi-Sun Ryu; Kang-Ho Choi; Jay Chol Choi; Joong-Goo Kim; Jee-Hyun Kwon; Wook-Joo Kim; Dong-Ick Shin; Kyu Sun Yum; Sung-Il Sohn; Jeong-Ho Hong; Chulho Kim; Sang-Hwa Lee; Juneyoung Lee; Mohammed A Almekhlafi; Andrew Demchuk; Hee-Joon Bae
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.